Idiopathic Pulmonary Fibrosis Registry for Future Studies

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Ohio State University
Sponsor:
Information provided by (Responsible Party):
Clay Marsh MD, The Ohio State University
ClinicalTrials.gov Identifier:
NCT00815711
First received: December 29, 2008
Last updated: February 11, 2014
Last verified: February 2014

December 29, 2008
February 11, 2014
December 2008
January 2015   (final data collection date for primary outcome measure)
Framework [ Time Frame: 7 + years ] [ Designated as safety issue: No ]
To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated
Not Provided
Complete list of historical versions of study NCT00815711 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Idiopathic Pulmonary Fibrosis Registry for Future Studies
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis

To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physiologic measures that follow patients through their course will allow the following proposed studies as well as future investigations to be efficiently carried out.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood serum BAL fluid lung biopsy

Non-Probability Sample

primary care clinic

  • Lung Disease, Interstitial
  • Idiopathic Pulmonary Fibrosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
84
January 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.

Exclusion Criteria:

  • pregnancy
  • inability to follow study requirements
Both
18 Years and older
No
Contact: Janice E Drake, CRTT 614-688-2287 janice.drake@osumc.edu
Contact: Sharon T Cheung, BS 614-366-2258 sharon.cheung@osumc.edu
United States
 
NCT00815711
2007H0002
No
Clay Marsh MD, The Ohio State University
Clay Marsh MD
Not Provided
Principal Investigator: Clay B Marsh, MD Ohio State University
Ohio State University
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP